New pharmaceutical combinations for NOS inhibitors
申请人:Pfizer Inc
公开号:US20040229911A1
公开(公告)日:2004-11-18
The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
[EN] NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS<br/>[FR] NOUVELLES COMBINAISONS PHARMACEUTIQUES POUR LES INHIBITEURS DE NOS
申请人:PFIZER PROD INC
公开号:WO2000071107A2
公开(公告)日:2000-11-30
The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
申请人:Pfizer Inc
公开号:US20040142924A1
公开(公告)日:2004-07-22
The present invention relates to 6-phenyl-pyridin-2-ylamine derivatives of the formula
1
wherein G, R
1
and R
2
are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system and other disorders.